184 related articles for article (PubMed ID: 36105075)
1. An integrated pan-cancer analysis of PSAT1: A potential biomarker for survival and immunotherapy.
Feng M; Cui H; Tu W; Li L; Gao Y; Chen L; Li D; Chen X; Xu F; Zhou C; Cao Y
Front Genet; 2022; 13():975381. PubMed ID: 36105075
[TBL] [Abstract][Full Text] [Related]
2. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
3. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of PSAT1 is Correlated with Poor Prognosis and Immune Infiltration in Non-Small Cell Lung Cancer.
Li H; Wu C; Chang W; Zhong L; Gao W; Zeng M; Wen Z; Mai S; Chen Y
Front Biosci (Landmark Ed); 2023 Oct; 28(10):243. PubMed ID: 37919070
[TBL] [Abstract][Full Text] [Related]
5. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.
Wu J; Yu X; Zhu H; Chen P; Liu T; Yin R; Qiang Y; Xu L
Front Mol Biosci; 2023; 10():1178446. PubMed ID: 37388242
[No Abstract] [Full Text] [Related]
6. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
[No Abstract] [Full Text] [Related]
7. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
8. A pan-cancer analysis of FAT atypical cadherin 4 (FAT4) in human tumors.
Mao W; Zhou J; Hu J; Zhao K; Fu Z; Wang J; Mao K
Front Public Health; 2022; 10():969070. PubMed ID: 36051999
[TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
11. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
12. CCL5 might be a prognostic biomarker and associated with immuno-therapeutic efficacy in cancers: A pan-cancer analysis.
Huang Y; Wu L; Sun Y; Li J; Mao N; Yang Y; Zhao M; Ren S
Heliyon; 2023 Jul; 9(7):e18215. PubMed ID: 37519664
[TBL] [Abstract][Full Text] [Related]
13. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2 Serves as a Prognostic Biomarker and Correlated With Immune Infiltrates in Breast Invasive Cancer and Lung Adenocarcinoma.
Xiao X; Shan H; Niu Y; Wang P; Li D; Zhang Y; Wang J; Wu Y; Jiang H
Front Mol Biosci; 2022; 9():647826. PubMed ID: 35558557
[TBL] [Abstract][Full Text] [Related]
15. ANXA2 is a potential biomarker for cancer prognosis and immune infiltration: A systematic pan-cancer analysis.
Ning Y; Li Y; Wang H
Front Genet; 2023; 14():1108167. PubMed ID: 36713082
[No Abstract] [Full Text] [Related]
16. Preliminary exploration of the potential biological functions and prognosis values of RAB4B in pan-cancer combing with experimental validation in BLCA.
Li K; Liang S; Mi H
Transl Cancer Res; 2024 Feb; 13(2):613-633. PubMed ID: 38482438
[TBL] [Abstract][Full Text] [Related]
17. UBE2C is a diagnosis and therapeutic biomarker involved in immune infiltration of cancers including lung adenocarcinoma.
Cai D; Tian F; Wu M; Tu J; Wang Y
J Cancer; 2024; 15(6):1701-1717. PubMed ID: 38370368
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Immunological Significance of ANKRD52 in Pan-Cancer.
Yin HZ; Zhang MC; Wu H
Biochem Genet; 2024 Jan; ():. PubMed ID: 38296907
[TBL] [Abstract][Full Text] [Related]
20. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]